Recent News

• 11.04.2026 - Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
• 11.03.2026 - Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
• 10.20.2026 - Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
• 09.02.2026 - Ascentage Pharma to Participate in Four Upcoming Investor Conferences
• 08.19.2026 - Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates
• 08.13.2026 - Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit
• 08.05.2026 - CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
• 08.05.2026 - Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026
• 08.02.2026 - Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer
• 07.26.2026 - Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026

Recent Filings

• 10.28.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.28.2026 - EX-99.1 EX-99.1
• 10.22.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.22.2026 - EX-99.1 EX-99.1
• 10.21.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.21.2026 - EX-99.1 EX-99.1
• 10.15.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.15.2026 - EX-99.1 EX-99.1
• 09.29.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.29.2026 - EX-99.1 EX-99.1